Gastrointestinal Manifestations and Associated Health Outcomes of COVID-19: A Brazilian Experience From the Largest South American Public Hospital

Proença, Igor Mendonça; McCarty, Thomas R.; Sagae, Vitor Massaro Takamatsu; Ribeiro, Igor Braga; Oliveira, Guilherme Henrique Peixoto de; Souza, Gabriel Mayo Vieira de; Hirsch, Bruno Salomão; Scatimburgo, Maria Vitória Cury Vieira; Thompson, Christopher D.; Carrilho, Flair José; Cecconello, Ivan; Moura, Eduardo Guimarães Hourneaux de

doi:10.6061/clinics/2020/e2271

Cited by 21 publications

(21 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Establishing a correct diagnosis is challenging due to the nonspecific clinical signs/symptoms, which may not result in suspicions of mucormycosis. The endoscopic appearance of gastric mucormycosis is usually a large ulcer with necrosis, eventually presenting an adherent, thick, green exudate [ 13 , 14 ]. Diagnosis is confirmed by histopathologic identification based on the biopsy of the suspected area during surgery or endoscopy [ 6 ].…”

Section: Discussionmentioning

confidence: 99%

Rare and Fatal Gastrointestinal Mucormycosis (Zygomycosis) in a COVID-19 Patient: A Case Report

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Rare and Fatal Gastrointestinal Mucormycosis (Zygomycosis) in a COVID-19 Patient: A Case Report

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…The prevalence of GI and hepatic manifestations of COVID-19 is variable across studies from different regions, as highlighted in the data from meta-analyses (Table 1) [7][8][9][10][11][12][13] and individual studies ( Table 2). [14][15][16][17][18][19] In addition, endemic areas are associated with co-infections, such as acute viral hepatitis, and tropical infections, such as malaria and dengue. [20][21][22]…”

Section: Liver Manifestations Of Covid-19mentioning

confidence: 99%

Coronavirus Disease-2019 (COVID-19) and the Liver

Elhence¹,

Vaishnav²,

Biswas³

et al. 2021

Journal of Clinical and Translational Hepatology

View full text Add to dashboard Cite

Within a year of its emergence, coronavirus disease-2019 (COVID-19) has evolved into a pandemic. What has emerged during the past 1 year is that, apart from its potentially fatal respiratory presentation from which the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) derives its name, it presents with a myriad of gastrointestinal (GI) and liver manifestations. Expression of the angiotensinconverting enzyme-2 (ACE-2) receptor throughout the GI tract and liver, which is the receptor for the SARS-CoV-2, may be responsible for the GI and liver manifestations. Besides acting directly via the ACE-2 receptor, the virus triggers a potent immune response, which might have a role in pathogenesis. The virus leads to derangement in liver function tests in close to 50% of the patients. The impact of these derangements in patients with a normal underlying liver seems to be innocuous. Severe clinical presentations include acute decompensation and acute-on-chronic liver failure in a patient with chronic liver disease, leading to high mortality. Evolving data suggests that, contrary to intuition, liver transplant recipients and patients with autoimmune liver disease on immunosuppression do not have increased mortality. The exact mechanism underlying why immunosuppressed patients fare well as compared to other patients remains to be deciphered. With newer variants of COVID-19, which can spread faster than the original strain, the data on hepatic manifestations needs to be updated to keep a step ahead of the virus.

show abstract

“…Fever and respiratory symptoms were most common among the patients, reported in numerous other studies [21,27,28]. While several studies from China [28,29], Uzbekistan [30], and Brazil [31] reported weakness or fatigue as a common symptom, only 8% (n = 31 out of 377) of the patients reported that they experienced weakness during initial triage at the hospital.…”

Section: Discussionmentioning

confidence: 81%

Clinical profile and short-term outcomes of RT-PCR positive COVID-19 patients in a tertiary care hospital in Dhaka, Bangladesh

Hasan

Biswas²,

Am³

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: After one year since emerging from Wuhan, China, the Coronavirus disease 2019 (COVID-19) pandemic is still raging worldwide. Still, there is a dearth of original research exploring the attributes of COVID-19 patients from lower-and middle-income countries, such as Bangladesh. Based on a case series from a tertiary healthcare center, this observational study has explored the epidemiological and clinical profile of COVID-19 patients in Dhaka, Bangladesh. A total of 422 COVID-19 confirmed patients (via Reverse transcription-polymerase chain reaction test) were enrolled in this study. We have compiled patients' medical records and reported their demographic, socioeconomic, and clinical features, treatment history, health outcome, and post-discharge complications descriptively.Result: Patients were predominantly male (64%), between 35 to 49 years (28%), with at least one comorbidity (52%), and had COVID-19 symptoms for one week before hospitalization (66%). A significantly higher proportion (P<0.05) of male patients had diabetes, hypertension, and ischemic heart disease, while females had a significantly higher proportion (P<0.05) of asthma. The most common symptoms were fever (80%), cough (60%), dyspnea (41%), and sore throat (21%). Most patients received antibiotics (77%) and anticoagulant therapy (56%) and stayed in the hospital for an average of 12 days. Over 90% of patients were successfully weaned, while 3% died from COVID-19, and 41% reported complications after discharge.Conclusion: The diversity of clinical and epidemiological characteristics and health outcomes of COVID-19 patients across age groups and gender is noteworthy. Our result will inform the clinicians and epidemiologists of Bangladesh of their COVID-19 mitigation effort.

show abstract

Gastrointestinal Manifestations and Associated Health Outcomes of COVID-19: A Brazilian Experience From the Largest South American Public Hospital

Cited by 21 publications

References 26 publications

Rare and Fatal Gastrointestinal Mucormycosis (Zygomycosis) in a COVID-19 Patient: A Case Report

Rare and Fatal Gastrointestinal Mucormycosis (Zygomycosis) in a COVID-19 Patient: A Case Report

Coronavirus Disease-2019 (COVID-19) and the Liver

Clinical profile and short-term outcomes of RT-PCR positive COVID-19 patients in a tertiary care hospital in Dhaka, Bangladesh

Contact Info

Product

Resources

About